Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 1

Pfizer Oncology Biologics and

Metabolic/Obesity Pipeline

Portfolio

STRATEGIC TRANSFORMATION AND INNOVATION

FRAMEWORK: A CASE STUDY IN GLOBAL

BIOPHARMACEUTICAL LEADERSHIP

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 2

Executive Overview: Strategic

Transformation

CORPORATE STRATEGY &

INNOVATION

Post-Pandemic Pivot

Following the historic deployment of COVID-19 vaccines and therapeutics, Pfizer is navigating a

strategic pivot toward sustainable long-term growth. This transition is characterized by a disciplined

reallocation of capital toward high-impact areas: Precision Oncology, Biologics, and Metabolic

Disease Innovation.

Core Strategic Pillars

The company's 'New Pfizer' strategy rests on four pillars: accelerating pipeline throughput,

expanding leadership in oncology through the Seagen acquisition, pioneering next-gen metabolic

therapies, and leveraging AI to compress clinical timelines.

Page 2

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 3

Oncology Biologics & Precision

Medicine

CORPORATE STRATEGY &

INNOVATION

A Diversified Modality Strategy

Pfizer's oncology strategy is built on a foundation of diverse modalities, including small molecules,

monoclonal antibodies, and most notably, the industry's leading Antibody-Drug Conjugate (ADC)

platform.

Therapeutic Focus Areas

The portfolio addresses high-unmet-need areas: Hematologic malignancies (Multiple Myeloma,

Lymphoma) and Solid Tumors (Breast, Genitourinary, and Thoracic cancers).

Page 3

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 4

Antibody-Drug Conjugate (ADC)

Leadership

CORPORATE STRATEGY &

INNOVATION

The Seagen Integration

The acquisition of Seagen has fundamentally transformed Pfizer's oncology capabilities, adding a

world-class ADC technology suite that combines potent cytotoxic payloads with highly specific

antibody targeting.

Flagship Assets

Assets like enfortumab vedotin (Padcev) and tisotumab vedotin represent the vanguard of this

platform, demonstrating significant efficacy in advanced cancers and serving as the backbone for

future combination therapies.

Page 4

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 5

Metabolic and Obesity Pipeline

Portfolio

CORPORATE STRATEGY &

INNOVATION

Entering the Obesity Era

Pfizer is aggressively expanding into the metabolic space, focusing on oral GLP-1 receptor agonists

and peptide engineering. The goal is to provide patient-centric alternatives to injectable therapies.

Scientific Workflow

Research targets the hormonal regulation of appetite and glucose metabolism, leveraging Pfizer's

deep expertise in small molecule design to create highly bioavailable oral treatments for obesity and

Type 2 diabetes.

Page 5

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 6

Clinical Research & Pipeline

Development

CORPORATE STRATEGY &

INNOVATION

Accelerating Lightspeed

Building on lessons from vaccine development, Pfizer applies 'Lightspeed' principles across its

portfolio to reduce Phase I to Phase III cycle times without compromising scientific rigor.

Evidence Generation

A robust focus on Real-World Evidence (RWE) and precision diagnostics ensures that clinical

programs are targeted toward the patient populations most likely to benefit, increasing the

probability of success (PoS).

Page 6

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 7

Advanced Manufacturing &

Infrastructure

CORPORATE STRATEGY &

INNOVATION

Biologics Scale-Up

Pfizer operates one of the world's largest biologics manufacturing networks. Investment in cell-

based production and digital twin technology allows for rapid scale-up of complex proteins and

ADCs.

Supply Chain Resilience

The 'Digital Factory' initiative integrates AI-driven demand forecasting and automated quality

control, ensuring a resilient supply of life-saving medicines to over 180 countries.

Page 7

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 8

Strategic Acquisitions &

Portfolio Expansion

CORPORATE STRATEGY &

INNOVATION

External Innovation Strategy

M&A is a core growth engine. Beyond Seagen, strategic investments in companies like Global Blood

Therapeutics and Arena Pharmaceuticals have bolstered Pfizer's rare disease and immunology

pipelines.

Partnership Ecosystems

Collaborations with academic centers and biotech startups ensure Pfizer remains at the forefront of

emerging modalities like gene editing and mRNA-based oncology vaccines.

Page 8

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 9

R&D, AI, and Precision

Medicine

CORPORATE STRATEGY &

INNOVATION

Computational Biology

Pfizer uses supercomputing and AI-driven protein folding models to identify novel drug targets. This

digital-first approach reduces the time spent in early-stage discovery from years to months.

Precision Medicine Ecosystem

By integrating genomic data with clinical trial results, Pfizer is moving toward a future of 'tailored

therapeutics' where treatment is optimized based on an individual's molecular profile.

Page 9

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 10

Portfolio Optimization & Capital

Allocation

CORPORATE STRATEGY &

INNOVATION

Disciplined Investment

Pfizer employs a rigorous stage-gate process for pipeline prioritization. Capital is aggressively

directed toward assets with 'Blockbuster' potential ($1B+ annual revenue) while non-core assets are

divested or out-licensed.

Shareholder Value

The strategy balances heavy R&D reinvestment with a commitment to dividend growth and share

repurchases, supported by a strong balance sheet and diversified revenue streams.

Page 10

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 11

Financial Performance &

Corporate Strategy

CORPORATE STRATEGY &

INNOVATION

Revenue Diversification

As patent cliffs for older assets approach, the focus shifts to the 'Class of 2024-2026'—a suite of new

launches expected to contribute significantly to the 2030 revenue target.

Operational Priorities

Margin expansion through operational efficiency and the realization of cost synergies from recent

acquisitions remain top priorities for the executive leadership team.

Page 11

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 12

Global Healthcare Impact &

Sustainability

CORPORATE STRATEGY &

INNOVATION

An Accord for a Healthier World

Pfizer's initiative to provide its full portfolio of patented medicines on a not-for-profit basis to 45

lower-income countries defines its commitment to global health equity.

Sustainability Commitments

The company is targeting Net-Zero by 2040, integrating green chemistry and sustainable packaging

across its global manufacturing and distribution footprint.

Page 12

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio — page 13

Conclusion: Executive

Outlook

CORPORATE STRATEGY &

INNOVATION

The Road Ahead

Pfizer enters 2027 as a leaner, more focused oncology and biologics powerhouse. By integrating

breakthrough science with world-class manufacturing, the company is uniquely positioned to

redefine the standard of care for millions of patients.

Page 13

Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio

Prompt to Clone This Pfizer Oncology Biologics and Metabolic/Obesity Pipeline Portfolio

Apply this example's core structure, strategic pacing, and structural hierarchy directly to your own topic.

What are you generating today?